Vertex Pharmaceuticals Financial Ratios
NASDAQ: VRTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Vertex Pharmaceuticals ratio analysis
Vertex Pharmaceuticals earned a net margin of 32.9% in FY 2025, up from -4.9% a year earlier. Gross margin was 86.2% compared with a median of 87.6% over the prior 9 years. Return on equity reached 21.2%, meaning Vertex Pharmaceuticals generated 0.21 dollars of profit for every dollar of shareholders' equity.
At the end of FY 2025, VRTX traded at 29.5 times earnings; across the 8 fiscal years shown, its year-end P/E ranged from 21.3 to 144.1, with a median of 26.8. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Vertex Pharmaceuticals financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 29.51 | — | 29.29 | 22.53 | 24.37 | 22.97 | 48.33 | 21.35 | 144.10 | — |
| Price / sales | 9.63 | 9.53 | 10.62 | 8.28 | 7.47 | 9.89 | 13.44 | 14.41 | 14.99 | 10.59 |
| Price / book | 6.19 | 6.40 | 5.96 | 5.32 | 5.60 | 7.07 | 9.20 | 9.90 | 18.38 | 15.59 |
| Gross margin | 86.2% | 86.1% | 87.2% | 87.9% | 88.1% | 88.1% | 86.8% | 86.6% | 88.9% | 87.6% |
| Operating margin | 34.8% | -2.1% | 38.8% | 48.2% | 36.7% | 46.0% | 28.8% | 20.8% | 5.0% | 0.6% |
| Net margin | 32.9% | -4.9% | 36.7% | 37.2% | 30.9% | 43.7% | 28.3% | 68.8% | 10.6% | -6.6% |
| Free cash flow margin | 26.6% | -7.2% | 33.8% | 44.0% | 31.8% | 48.2% | 35.9% | 38.5% | 30.0% | 10.5% |
| Return on equity (ROE) | 21.2% | -3.3% | 20.6% | 23.9% | 23.2% | 31.2% | 19.3% | 47.3% | 13.0% | -9.7% |
| Return on assets (ROA) | 15.4% | -2.4% | 15.9% | 18.3% | 17.4% | 23.1% | 14.1% | 33.6% | 7.4% | -3.9% |
| Debt / equity | — | — | — | — | — | — | — | — | — | 0.00 |
| Current ratio | 2.90 | 2.69 | 3.99 | 4.83 | 4.46 | 4.33 | 3.61 | 3.43 | 3.28 | 2.31 |
| Revenue growth | 8.9% | 11.7% | 10.5% | 17.9% | 22.1% | 49.1% | 36.6% | 22.5% | 46.2% | 64.9% |
| EPS growth | — | -115.0% | 8.3% | 42.3% | -12.4% | 128.2% | -44.3% | 677.9% | — | — |